Patricia Osborne
Family · Hillsville, VANPI 1043646904
Payments from drug & device makers
Across 100 payments — averaging $18.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$430
- Novo Nordisk$346
- Pfizer$127
- Verona Pharma, Inc.$106
- Exact Sciences$104
- Mylan Specialty L.p.$75
- plus $612 from 19 others
What the payments were for
- Food & beverage$1,802100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 24 | $430 |
| Novo Nordisk | 21 | $346 |
| Pfizer | 7 | $127 |
| Verona Pharma, Inc. | 5 | $106 |
| Exact Sciences | 5 | $104 |
| Mylan Specialty L.p. | 3 | $75 |
| AbbVie | 4 | $62 |
| Lilly USA, LLC | 3 | $58 |
| Xeris Pharmaceuticals, Inc. | 3 | $53 |
| Amgen | 3 | $52 |
| Phathom Pharmaceuticals, Inc. | 3 | $50 |
| Bayer | 2 | $49 |
| Sanofi-aventis U.S. LLC | 3 | $48 |
| Abbott | 3 | $39 |
| Dexcom, Inc. | 1 | $28 |
| Insulet Corporation | 1 | $23 |
| Boehringer Ingelheim | 1 | $22 |
| Acrotech Biopharma Inc. | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Eisai Inc. | 1 | $12 |
| Genentech USA, Inc. | 1 | $10 |
How this compares
$1,802 in reported general payments places this provider in the 80th percentile of 4,332 family providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 94 | $98,432 |
| EliquisApixaban | 85 | $76,419 |
| TrulicityDulaglutide | 45 | $75,974 |
| JardianceEmpagliflozin | 59 | $75,454 |
| OzempicSemaglutide | 30 | $51,665 |
| XareltoRivaroxaban | 27 | $33,152 |
| Breo ElliptaFluticasone/Vilanterol | 58 | $28,612 |
| Tresiba Flextouch U-100Insulin Degludec | 30 | $27,733 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $25,597 |
| LinzessLinaclotide | 16 | $24,616 |
| Spiriva HandihalerTiotropium Bromide | 20 | $16,265 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 26 | $12,066 |
| MyrbetriqMirabegron | 17 | $8,524 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 51 | $7,471 |
| Incruse ElliptaUmeclidinium Bromide | 17 | $5,919 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Symbicort | $430 | $103,481111 claims |
| PfizerEliquis | $127 | $76,41985 claims |
| Lilly USA, LLCTrulicity | $58 | $75,97445 claims |
| Boehringer IngelheimJardiance | $22 | $75,45459 claims |
| Novo NordiskOzempic | $346 | $51,66530 claims |
| Johnson & JohnsonXarelto | $19 | $33,15227 claims |
| AbbVieLinzess, Synthroid | $62 | $25,95348 claims |
| Astellas Pharma US IncMyrbetriq | $15 | $8,52417 claims |
| Sanofi-aventis U.S. LLCLantus | $48 | $2,25421 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,332 family providers in Virginia.
Other family in Hillsville
- Andrea CottonVirginia Beach$696K
- Susan MooreWytheville$438K
- Ellen WermterCharlottesville$251K
- Dana StallingsFranklin$225K
- Jocelyn BrackettHerndon$199K
- Hochong Smith GillesRichmond$131K
- Sean OlaughlinMidlothian$110K
- Adam MedlinHampton$67K
- Casey SharpDanville$63K
- Norman JacobowitzManassas$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.